While NACT is a less common treatment choice in early ER+/HER2- breast cancer, identifying better biomarkers to optimally predict long-term response could make NACT a more viable option, enabling response-adapted treatment allocation during the neoadjuvant or adjuvant treatment phases and facilitating the identification of high-risk patients and patients with predicted favorable outcomes. This evidence concerns the gene ESR1 and breast cancer.